← Leaderboards
Christopher Vakoc
Cold Spring Harbor Laboratory
$22,318,597
Attributed
$23,379,377
Total exposure
17
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,875,376 · 18
By mechanism
P01$15,912,425 · 7
R01$11,869,689 · 4
U01$2,178,432 · 1
P30$1,421,150 · 5
R21$493,680 · 1
Top collaborators
- Yan Jessie Zhang3 shared
Most similar at Cold Spring Harbor Laboratory
Same institution · by research overlap
- Gregory J Hannon$22,911,444
- David L Spector$29,409,281
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsDependenceProgramsComplexGenesCrispr ScreenIn VivoInnovationGenetic ScreeningProteinsExperimental StudyGenetic TranscriptionClustered Regularly Interspaced Short Palindromic RepeatsMolecularCancer CellGeneticTranscription FactorCellsMaintenanceBiochemicalTherapeutic TargetEpigenetic ProcessMemberTechnology
Grant awards (59)
Targeting Transcription and Splicing in Cancer$2,880,000
P01 · FY2025 · CA · contact PI
Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia$709,633
R01 · FY2025 · CA · contact PI
Biology and vulnerabilities of POU2F3+ tuft cell-like carcinomas$673,208
R01 · FY2025 · CA · contact PI
Project 1: Targeting Oncogenic Transcription Factors$662,404
P01 · FY2025 · CA · contact PI
Targeting aberrant enhancer landscapes in pancreatic cancer$432,000
R01 · FY2025 · CA · contact PI
Core A: Administration$207,358
P01 · FY2025 · CA · contact PI
Functional Genomics Shared Resource$150,618
P30 · FY2025 · CA · contact PI
Cancer Genetics and Genomics Program$45,765
P30 · FY2025 · CA · contact PI
Targeting Transcription and Splicing in Cancer$2,735,999
P01 · FY2024 · CA · contact PI
Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia$669,389
R01 · FY2024 · CA · contact PI
Biology and vulnerabilities of POU2F3+ tuft cell-like carcinomas$668,427
R01 · FY2024 · CA · contact PI
Project 1: Targeting Oncogenic Transcription Factors$655,771
P01 · FY2024 · CA · contact PI
Targeting aberrant enhancer landscapes in pancreatic cancer$432,000
R01 · FY2024 · CA · contact PI
Core A: Administration$175,451
P01 · FY2024 · CA · contact PI
Functional Genomics Shared Resource$155,573
P30 · FY2024 · CA · contact PI
Cancer Genetics and Genomics Program$55,966
P30 · FY2024 · CA · contact PI
Targeting Transcription and Splicing in Cancer$2,880,000
P01 · FY2023 · CA · contact PI
Elucidating the SCP4 pathway as a multi-catalytic signaling dependency in acute myeloid leukemia$742,538
R01 · FY2023 · CA · contact PI
Project 1: Targeting Oncogenic Transcription Factors$662,400
P01 · FY2023 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$541,142
R01 · FY2023 · CA · contact PI
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer$430,416
U01 · FY2023 · CA · contact PI
Targeting aberrant enhancer landscapes in pancreatic cancer$404,792
R01 · FY2023 · CA · contact PI
Core A: Administration$207,360
P01 · FY2023 · CA · contact PI
Functional Genomics Shared Resource$150,618
P30 · FY2023 · CA · contact PI
Cancer Genetics and Genomics Program$45,765
P30 · FY2023 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$541,142
R01 · FY2022 · CA · contact PI
Project 4: Transcriptional Coactivators and Enhancers in Human Cancer$540,262
P01 · FY2022 · CA · contact PI
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer$430,416
U01 · FY2022 · CA · contact PI
Core B: Gene Modulation with RNAi and CRISPER$418,176
P01 · FY2022 · CA · contact PI
Targeting aberrant enhancer landscapes in pancreatic cancer$404,792
R01 · FY2022 · CA · contact PI
Functional Genomics Shared Resource$150,618
P30 · FY2022 · CA · contact PI
Cancer Genetics and Genomics Program$45,765
P30 · FY2022 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$552,186
R01 · FY2021 · CA · contact PI
Project 4: Transcriptional Coactivators and Enhancers in Human Cancer$551,286
P01 · FY2021 · CA · contact PI
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer$439,200
U01 · FY2021 · CA · contact PI
Core B: Gene Modulation with RNAi and CRISPER$426,712
P01 · FY2021 · CA · contact PI
Targeting aberrant enhancer landscapes in pancreatic cancer$413,053
R01 · FY2021 · CA · contact PI
Elucidating the function of PAX3-FOXO1 in rhabdomyosarcoma with molecular reporters and next-generation genome editing$224,400
R21 · FY2021 · CA · contact PI
Functional Genomics Shared Resource$150,618
P30 · FY2021 · CA · contact PI
Cancer Genetics and Genomics Program$45,765
P30 · FY2021 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$552,186
R01 · FY2020 · CA · contact PI
Project 4: Transcriptional Coactivators and Enhancers in Human Cancer$551,286
P01 · FY2020 · CA · contact PI
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer$439,200
U01 · FY2020 · CA · contact PI
Core B: Gene Modulation with RNAi and CRISPER$426,712
P01 · FY2020 · CA · contact PI
Functional Genomics and Genetics Shared Resource$424,079
P30 · FY2020 · CA · contact PI
Targeting aberrant enhancer landscapes in pancreatic cancer$413,053
R01 · FY2020 · CA · contact PI
Elucidating the function of PAX3-FOXO1 in rhabdomyosarcoma with molecular reporters and next-generation genome editing$269,280
R21 · FY2020 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$552,186
R01 · FY2019 · CA · contact PI
Project 4: Transcriptional Coactivators and Enhancers in Human Cancer$536,356
P01 · FY2019 · CA · contact PI
Exploiting POU2F3 addiction in the tuft cell variant of small cell lung cancer$439,200
U01 · FY2019 · CA · contact PI
Targeting aberrant enhancer landscapes in pancreatic cancer$413,053
R01 · FY2019 · CA · contact PI
Core B: Gene Modulation with RNAi and CRISPER$411,783
P01 · FY2019 · CA · contact PI
Project 4: Transcriptional Coactivators and Enhancers in Human Cancer$553,842
P01 · FY2018 · CA · contact PI
Core B: Gene Modulation with RNAi and CRISPER$429,267
P01 · FY2018 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$557,762
R01 · FY2017 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$557,762
R01 · FY2016 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$557,762
R01 · FY2015 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$532,576
R01 · FY2014 · CA · contact PI
BET bromodomain inhibition as targeted therapy in acute myeloid leukemia$549,047
R01 · FY2013 · CA · contact PI